Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PER2 | O15055 | 5/20 | 0.40 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | BRD4 | O60885 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | GBA1 | P04062 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
| ▸ | PRKCD | Q05655 | 4/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6287632 | 0.95 | PER2 (0.40) | PER2CRY2HTTALDH1A1BRD4 | |
| SCHEMBL6284302 | 0.93 | PER2 (0.39) | PER2CRY2HTTALDH1A1BRD4 | |
| SCHEMBL2195365 | 0.89 | PER2 (0.42) | PER2CRY2ALDH1A1BRD4KMT2A | |
| SCHEMBL6285626 | 0.87 | PER2 (0.36) | PER2CRY2 | |
| SCHEMBL6562357 | 0.81 | PER2 (0.38) | PER2CRY2ALOX5 | |
| SCHEMBL757394 | 0.80 | — | — | |
| SCHEMBL6284636 | 0.79 | PER2 (0.36) | PER2CRY2HTTKMT2A | |
| SCHEMBL7465403 | 0.79 | PER2 (0.40) | PER2CRY2ALDH1A1L3MBTL1GBA1 | |
| SCHEMBL6284202 | 0.78 | PER2 (0.36) | PER2CRY2TSHRHTTKMT2A | |
| SCHEMBL6283893 | 0.77 | PER2 (0.35) | PER2CRY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9150673-B2 | Process for preparing (meth)acrylic esters | BASF SE (DE) | 2015-10-06 | — | — | US | disclosed |
| US-20130178592-A1 | PROCESS FOR PREPARING (METH)ACRYLIC ESTERS | BASF SE (DE) | 2013-07-11 | — | — | US | disclosed |
| US-8263371-B2 | Catalyzed preparation of (meth)acrylates of N-hydroxyalkylated amides | BASF AKTIENGESELLSCHAFT (DE) | 2012-09-11 | — | — | US | disclosed |
| US-7993886-B2 | Catalyzed preparation of (meth)acrylates of N-hydroxyalkylated amides | BASF AKTIENGESELLSHAFT (DE) | 2011-08-09 | — | — | US | disclosed |
| US-20110171697-A1 | CATALYZED PREPARATION OF (METH)ACRYLATES OF N-HYDROXYALKYLATED AMIDES | BASF AKTIENGESELLSHAFT (DE) | 2011-07-14 | — | — | US | disclosed |
| US-20100285542-A1 | CATALYZED PREPARATION OF (METH)ACRYLATES OF N-HYDROXYALKYLATED AMIDES | BASF AKTIENGESELLSHAFT (DE) | 2010-11-11 | — | — | US | disclosed |
| US-7816485-B2 | Catalyzed preparation of (meth)acrylates of N-hydroxyalkylated amides | BASF AKTIENGESELLSCHAFT (DE) | 2010-10-19 | — | — | US | disclosed |
| US-20060036063-A1 | Catalyzed preparation of (meth)acrylates of N-hydroxyalkylated amides | BASF AKTIENGESELLSCHAFT (DE) | 2006-02-16 | — | — | US | disclosed |
| US-6916854-B2 | Heat and/or light curable films or coatings comprising polyurethanes or polyureaurethane copolymers having storage stability, used as automobile paints | BASF AKTIENGESELLSCHAFT (DE) | 2005-07-12 | — | — | US | disclosed |
| US-20040097642-A1 | Unsaturated compounds containing carbamate terminal groups or urea terminal groups | BASF AKTIENGESELLSCHAFT (DE) | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100285542-A1 | CATALYZED PREPARATION OF (METH)ACRYLATES OF N-HYDROXYALKYLATED AMIDES | NAAA, APEH, NAA15 | PER2 3405/4885CRY2 4801/4885USP2 466/4885 |
| US-20110171697-A1 | CATALYZED PREPARATION OF (METH)ACRYLATES OF N-HYDROXYALKYLATED AMIDES | NAAA, APEH, NAA15 | PER2 3405/4885CRY2 4801/4885USP2 466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.